Toxicities associated with immunotherapies for hematologic malignancies

Best Practice & Research Clinical Haematology - Tập 31 - Trang 158-165 - 2018
Mark B. Leick1,2, Marcela V. Maus1,2
1Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA
2Harvard Medical School, Boston, MA, USA

Tài liệu tham khảo

Coley, 1893, The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases, Am J Med Sci, 1893, 487, 10.1097/00000441-189305000-00001

Thomas, 1975, Bone-marrow transplantation (first of two parts), N Engl J Med, 292, 832, 10.1056/NEJM197504172921605

Leukaemia, 1993, Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no-transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986, Br J Haematol, 85, 292, 10.1111/j.1365-2141.1993.tb03169.x

2018

Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

Neelapu, 2018, Chimeric antigen receptor T-cell therapy - assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148

Golay, 2014, A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy, J immunol (Baltimore, Md : 1950), 193, 4739, 10.4049/jimmunol.1401550

Topp, 2011, Targeted therapy with the T-cell–engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-Lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival, J Clin Oncol, 29, 2493, 10.1200/JCO.2010.32.7270

FDA grants regular approval to blinatumomab and expands indication to include Philadelphia chromosome-positive B cell [Website]. [updated 07/12/2017 Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm566708.htm.

Martinelli, 2017, Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-Precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study, J Clin Oncol : Off J Am Soc Clin Oncol, 35, 1795, 10.1200/JCO.2016.69.3531

Zugmaier, 2015, Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment, Blood, 126, 2578, 10.1182/blood-2015-06-649111

Blinatumomab [package insert], 2014

Bargou, 2008, Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science (New York, NY)., 321, 974, 10.1126/science.1158545

Topp, 2011, Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival, J Clin Oncol : Off J Am Soc Clin Oncol, 29, 2493, 10.1200/JCO.2010.32.7270

Kantarjian, 2017, Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia, N Engl J Med, 376, 836, 10.1056/NEJMoa1609783

Bondarenko, 2017, The efficacy and toxicity of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia: Russian multicenter experience, Blood, 130, 2604

Walunas, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 405, 10.1016/1074-7613(94)90071-X

Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science (New York, NY)., 271, 1734, 10.1126/science.271.5256.1734

Williams, 2006, Exhausted T cells perk up, Nature, 439, 669, 10.1038/439669a

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466

Monteiro, 2015, Timeline: checkpoint blockade, Cell, 162, 1434, 10.1016/j.cell.2015.08.019

Sadelain, 2017, Therapeutic T cell engineering, Nature, 545, 423, 10.1038/nature22395

Yarchoan, 2017, Tumor mutational burden and response rate to PD-1 inhibition, N Engl J Med, 377, 2500, 10.1056/NEJMc1713444

Postow, 2018, Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med, 378, 158, 10.1056/NEJMra1703481

Younes, 2016, Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, Lancet Oncol, 17, 1283, 10.1016/S1470-2045(16)30167-X

McClanahan, 2015, PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia, Blood, 126, 203, 10.1182/blood-2015-01-622936

Ding, 2017, Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL, Blood, 129, 3419, 10.1182/blood-2017-02-765685

Lesokhin, 2016, Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study, J Clin Oncol : Off J Am Soc Clin Oncol, 34, 2698, 10.1200/JCO.2015.65.9789

Ren, 2017, Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition, Clin Cancer Res : Off J Am Assoc Cancer Res, 23, 2255, 10.1158/1078-0432.CCR-16-1300

Li, 2017, Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors, Clin Cancer Res, 23, 6982, 10.1158/1078-0432.CCR-17-0867

Chong, 2017, PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR, Blood, 129, 1039, 10.1182/blood-2016-09-738245

Hill, 2017, Marked Re-Expansion of chimeric antigen receptor (CAR) T cells and tumor regression following nivolumab treatment in a patient treated with axicabtagene ciloleucel (axi-cel; KTE-C19) for refractory diffuse large B cell lymphoma (DLBCL), Blood, 130, 2825

Maude, 2017, The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL), J Clin Oncol, 35, 103, 10.1200/JCO.2017.35.15_suppl.103

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447

Sadelain, 2017, Therapeutic T cell engineering, Nature, 545, 423, 10.1038/nature22395

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842

Rosenbaum, 2017, Tragedy, perseverance, and chance — the story of CAR-T therapy, N Engl J Med, 377, 1313, 10.1056/NEJMp1711886

Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134

Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040

Perales, 2018, Building a safer and faster CAR: seatbelts, airbags, and CRISPR, Biol Blood Marrow Transplant : j Am Soc Blood Marrow Transplantat, 24, 27, 10.1016/j.bbmt.2017.10.017

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 10.1126/scitranslmed.3008226

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet (London, England), 385, 517, 10.1016/S0140-6736(14)61403-3

Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 10.1126/scitranslmed.aac5415

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Inman, 2017

Hu, 2016, Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy, J Hematol Oncol, 9, 70, 10.1186/s13045-016-0299-5

Santomasso, 2017, Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells, J Clin Oncol, 35, 3019, 10.1200/JCO.2017.35.15_suppl.3019

Turtle, 2017, Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells, J Clin Oncol, 35, 3020, 10.1200/JCO.2017.35.15_suppl.3020

Taraseviciute, 2016, Creation of the first non-human primate model that faithfully recapitulates chimeric antigen receptor (CAR) T cell-mediated cytokine release syndrome (CRS) and neurologic toxicity following B cell-directed CAR-T cell therapy, Blood, 128, 651, 10.1182/blood.V128.22.651.651

Tang, 2011, Advances in hemophagocytic lymphohistiocytosis: pathogenesis, early diagnosis/differential diagnosis, and treatment, Sci World J, 11, 10.1100/tsw.2011.62

Ramos-Casals, 2014, Adult haemophagocytic syndrome, Lancet (London, England)., 383, 1503, 10.1016/S0140-6736(13)61048-X

Prof, 2015, A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH, Blood, 126

Teachey, 2013, Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy, Blood, 121, 5154, 10.1182/blood-2013-02-485623

Schram, 2015, How I treat hemophagocytic lymphohistiocytosis in the adult patient, Blood, 125, 2908, 10.1182/blood-2015-01-551622

Lamers, 2013, Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity, Mol Ther : j Am Soc Gene Ther, 21, 904, 10.1038/mt.2013.17

Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24, e20, 10.1200/JCO.2006.05.9964

Cameron, 2013, Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells, Sci Transl Med, 5, 10.1126/scitranslmed.3006034

Maus, 2013, T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer Immunol Res, 1, 26, 10.1158/2326-6066.CIR-13-0006

Frigault, 2015, Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells, Cancer Immunol Res, 3, 356, 10.1158/2326-6066.CIR-14-0186

Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838

Brudno, 2016, Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-Cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease, J Clin Oncol, 34, 1112, 10.1200/JCO.2015.64.5929

Yang, 2015, Challenges and opportunities of allogeneic donor-derived CAR T cells, Curr Opin Hematol, 22, 509, 10.1097/MOH.0000000000000181

1992, Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer, J Exp Med, 176, 1125, 10.1084/jem.176.4.1125

Scholler, 2012, Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells, Sci Transl Med, 4, 10.1126/scitranslmed.3003761

Hacein-Bey-Abina, 2008, Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1, J Clin Invest, 118, 3132, 10.1172/JCI35700

Eyquem, 2017, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature, 543, 113, 10.1038/nature21405

Morgan, 2013, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy, J immunother (Hagerstown, Md : 1997), 36, 133

Parkhurst, 2011, T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis, Mol Ther : j Am Soc Gene Ther, 19, 620, 10.1038/mt.2010.272

Johnson, 2009, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714

Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol Ther : j Am Soc Gene Ther, 18, 843, 10.1038/mt.2010.24

Wang, 2017, Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial, Clin Cancer Res : Off J Am Assoc Cancer Res, 23, 1156, 10.1158/1078-0432.CCR-16-1365

Ramos, 2016, Clinical responses with T lymphocytes targeting malignancy-associated κ light chains, J Clin Invest, 126, 2588, 10.1172/JCI86000

Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729

Thông tin
Thông tin xuất bản

Best Practice & Research Clinical Haematology

Tập 31

158-165

Thông tin tác giả